General Information of Drug Off-Target (DOT) (ID: OTLPAX4N)

DOT Name Kinesin-like protein KIF2B (KIF2B)
Gene Name KIF2B
Related Disease
High blood pressure ( )
Coronary atherosclerosis ( )
Coronary heart disease ( )
Prostate cancer ( )
Prostate carcinoma ( )
UniProt ID
KIF2B_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Pfam ID
PF00225
Sequence
MASQFCLPESPCLSPLKPLKPHFGDIQEGIYVAIQRSDKRIHLAVVTEINRENYWVTVEW
VEKAVKKGKKIDLETILLLNPALDSAEHPMPPPPLSPLALAPSSAIRDQRTATKWVAMIP
QKNQTASGDSLDVRVPSKPCLMKQKKSPCLWEIQKLQEQREKRRRLQQEIRARRALDVNT
RNPNYEIMHMIEEYRRHLDSSKISVLEPPQEHRICVCVRKRPLNQRETTLKDLDIITVPS
DNVVMVHESKQKVDLTRYLQNQTFCFDHAFDDKASNELVYQFTAQPLVESIFRKGMATCF
AYGQTGSGKTYTMGGDFSGTAQDCSKGIYALVAQDVFLLLRNSTYEKLDLKVYGTFFEIY
GGKVYDLLNWKKKLQVLEDGNQQIQVVGLQEKEVCCVEEVLNLVEIGNSCRTSRQTPVNA
HSSRSHAVFQIILKSGRIMHGKFSLVDLAGNERGADTTKASRKRQLEGAEINKSLLALKE
CILALGQNKPHTPFRASKLTLVLRDSFIGQNSSTCMIATISPGMTSCENTLNTLRYANRV
KKLNVDVRPYHRGHYPIGHEAPRMLKSHIGNSEMSLQRDEFIKIPYVQSEEQKEIEEVET
LPTLLGKDTTISGKGSSQWLENIQERAGGVHHDIDFCIARSLSILEQKIDALTEIQKKLK
LLLADLHVKSKVE
Function Plus end-directed microtubule-dependent motor required for spindle assembly and chromosome movement. Has microtubule depolymerization activity. Plays a role in chromosome congression.
Tissue Specificity Highest level in lung. High level in ovary, moderate levels in heart, kidney, placenta, skeletal muscle and spleen (at protein level). Pancreas and spleen express a shorter isoform (at protein level).
KEGG Pathway
Motor proteins (hsa04814 )
Reactome Pathway
MHC class II antigen presentation (R-HSA-2132295 )
Separation of Sister Chromatids (R-HSA-2467813 )
Resolution of Sister Chromatid Cohesion (R-HSA-2500257 )
RHO GTPases Activate Formins (R-HSA-5663220 )
COPI-dependent Golgi-to-ER retrograde traffic (R-HSA-6811434 )
Mitotic Prometaphase (R-HSA-68877 )
EML4 and NUDC in mitotic spindle formation (R-HSA-9648025 )
Kinesins (R-HSA-983189 )
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal (R-HSA-141444 )

Molecular Interaction Atlas (MIA) of This DOT

5 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
High blood pressure DISY2OHH Strong Genetic Variation [1]
Coronary atherosclerosis DISKNDYU Limited Genetic Variation [2]
Coronary heart disease DIS5OIP1 Limited Genetic Variation [2]
Prostate cancer DISF190Y Limited Genetic Variation [3]
Prostate carcinoma DISMJPLE Limited Genetic Variation [3]
------------------------------------------------------------------------------------
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
1 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Methotrexate DM2TEOL Approved Methotrexate increases the expression of Kinesin-like protein KIF2B (KIF2B). [4]
------------------------------------------------------------------------------------
1 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene increases the methylation of Kinesin-like protein KIF2B (KIF2B). [5]
------------------------------------------------------------------------------------

References

1 Gene-environmental effects behind leukoaraiosis: a silent genetic variant of the kinesin protein can be activated in a subject with poorly controlled long-lasting hypertension.Clin Biochem. 2009 May;42(7-8):630-3. doi: 10.1016/j.clinbiochem.2008.11.003. Epub 2008 Nov 18.
2 Impact of KIF6 Polymorphism rs20455 on Coronary Heart Disease Risk and Effectiveness of Statin Therapy in 100 Patients from Southern Iran.Arch Iran Med. 2015 Oct;18(10):683-7.
3 Mutational landscape of candidate genes in familial prostate cancer.Prostate. 2014 Oct;74(14):1371-8. doi: 10.1002/pros.22849. Epub 2014 Aug 11.
4 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
5 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.